Ciliary neurotrophic factor
Latest Information Update: 09 Sep 1997
At a glance
- Originator Fidia Farmaceutici; Roche Palo Alto LLC
- Developer Roche Palo Alto LLC
- Class Eye disorder therapies; Obesity therapies
- Mechanism of Action Ciliary neurotrophic factor replacements
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis